Cyclophosphamide Added to Standard Immunosuppressive Therapy With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02828592` - Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia	Phase 2
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00004143` - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes	Phase 2
Recruiting	`NCT05012111` - Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
Recruiting	`NCT03836690` - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation	Phase 1
Recruiting	`NCT06039436` - Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
Enrolling by invitation	`NCT05049668` - RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
Recruiting	`NCT01351545` - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting	`NCT01472055` - Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT01703169` - Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia	Phase 2
Withdrawn	`NCT01129323` - Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia	N/A
Completed	`NCT00516152` - Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT	Phase 2
Recruiting	`NCT06069180` - The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA	Phase 4
Recruiting	`NCT03579875` - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders	Phase 2
Recruiting	`NCT05720234` - Avatrombopag Combined With IST as First-line Treatment for SAA	Phase 2
Recruiting	`NCT04304820` - Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)	Phase 2
Terminated	`NCT00358657` - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders	Phase 2
Completed	`NCT02998645` - Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia	Phase 2
Active, not recruiting	`NCT03825744` - Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia	Phase 3

NCT number	NCT05975996
Study type	Interventional
Source	Institute of Hematology & Blood Diseases Hospital
Contact	Liwei Fang, MD
Phone	13752253515
Email	fangliwei@ihcams.ac.cn
Status	Recruiting
Phase	Phase 2
Start date	July 10, 2023
Completion date	June 30, 2027

Cyclophosphamide Added to Standard Immunosuppressive Therapy With Eltrombopag as Front-line Therapy in Patients With Severe Aplastic Anemia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms